8082-737-676
Kalkine 0
countryflagUK
L

SMSN 966.0 -2.1772% TYT 2522.0 0.0% SMSD 804.0 -2.1898% SMSN 960.0 -2.7848% RIGD 58.4 1.7422% RIGD 57.4 -0.1739% SHEL 2439.0 0.1848% AZN 10124.0 -1.2678% BHP 1751.0 0.2577% HSBA 789.0 0.165% ULVR 4806.0 1.2003% CYPC 40.6 0.0% RIO 4398.0 1.0338% LLPC 1.5015 -99.0% DGED 109.53 1.0238% BP 359.4 1.4538% SBID 92.6 3.118% DGE 2071.0 -0.3369% GSK 1336.5 -0.6689% REL 3939.0 0.613%
SMSN 966.0 -2.1772% TYT 2522.0 0.0% SMSD 804.0 -2.1898% SMSN 960.0 -2.7848% RIGD 58.4 1.7422% RIGD 57.4 -0.1739% SHEL 2439.0 0.1848% AZN 10124.0 -1.2678% BHP 1751.0 0.2577% HSBA 789.0 0.165% ULVR 4806.0 1.2003% CYPC 40.6 0.0% RIO 4398.0 1.0338% LLPC 1.5015 -99.0% DGED 109.53 1.0238% BP 359.4 1.4538% SBID 92.6 3.118% DGE 2071.0 -0.3369% GSK 1336.5 -0.6689% REL 3939.0 0.613%

AstraZeneca PLC

Healthcare GB AZN

10124.0GBX
-130.0(1.27%)

Last update at 2025-04-17T15:42:00Z

Day Range

10048.0010202.00
LowHigh

52 Week Range

9778.0012312.43
LowHigh

Fundamentals

  • Previous Close 10254.00
  • Market Cap161750.70M
  • Volume2267937
  • P/E Ratio34.90
  • Dividend Yield2.24%
  • EBITDA18706.00M
  • Revenue TTM44994.00M
  • Revenue Per Share TTM29.05
  • Gross Profit TTM 35732.00M
  • Diluted EPS TTM2.99

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-310M5000M10000M15000M20000M25000M30000M35000M40000M
Total Revenue
Net Income

Balancesheet

2018-12-312019-12-312020-12-312021-12-312022-12-310M10000M20000M30000M40000M50000M60000M70000M80000M90000M100000M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-1500M-1000M-500M0M500M1000M1500M2000M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-312000M3000M4000M5000M6000M7000M8000M9000M10000M

Dividends Paid

2018-12-312019-12-312020-12-312021-12-312022-12-310M500M1000M1500M2000M2500M3000M3500M4000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 2501.00M -265.00000M 3916.00M 1548.00M 1993.00M
Minority interest -5.00000M -3.00000M 16.00M 1469.00M 1576.00M
Net income 3288.00M 112.00M 3196.00M 1335.00M 2155.00M
Selling general administrative 18955.00M 95.00M 11693.00M 12021.00M 10362.00M
Selling and marketing expenses 18955.00M 15680.00M 11693.00M 11848.00M 10362.00M
Gross profit 31960.00M 24980.00M 21318.00M 19463.00M 17154.00M
Reconciled depreciation 5480.00M 6530.00M 3149.00M 3762.00M 3753.00M
Ebit 3757.00M 1056.00M 5162.00M 2924.00M 3464.00M
Ebitda 9327.00M 7565.00M 8371.00M 7016.00M 7217.00M
Depreciation and amortization 5570.00M 6509.00M 3209.00M 4092.00M 3753.00M
Non operating income net other - - - - -
Operating income 3757.00M 1056.00M 5162.00M 2924.00M 1510.00M
Other operating expenses 40594.00M 36361.00M 21455.00M 21186.00M 20580.00M
Interest expense 1346.00M 1300.00M 1306.00M 1432.00M 1366.00M
Tax provision -792.00000M -380.00000M 772.00M 321.00M -57.00000M
Interest income 95.00M 43.00M 87.00M 145.00M 132.00M
Net interest income -1251.00000M -1257.00000M -1219.00000M -1237.00000M -1228.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -792.00000M -380.00000M 772.00M 321.00M -57.00000M
Total revenue 44351.00M 37417.00M 26617.00M 24384.00M 22090.00M
Total operating expenses 28203.00M 23924.00M 16156.00M 16265.00M 15644.00M
Cost of revenue 12391.00M 12437.00M 5299.00M 4921.00M 4936.00M
Total other income expense net -1256.00000M -1321.00000M -1246.00000M -1376.00000M 483.00M
Discontinued operations - - - - -
Net income from continuing ops 3293.00M 115.00M 3144.00M 1227.00M 2050.00M
Net income applicable to common shares 3288.00M 112.00M 3196.00M 1335.00M 2155.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 96483.00M 105363.00M 66729.00M 61377.00M 60651.00M
Intangible assets 39307.00M 42387.00M 20947.00M 20833.00M 21959.00M
Earning assets - - - - -
Other current assets 11489.00M 105.00M 7570.00M 6190.00M 7147.00M
Total liab 59425.00M 66076.00M 51091.00M 46781.00M 46607.00M
Total stockholder equity 37037.00M 39268.00M 15622.00M 13127.00M 12468.00M
Deferred long term liab - - - - -
Other current liab 1711.00M 1763.00M 2136.00M 2120.00M 11450.00M
Common stock 387.00M 387.00M 328.00M 328.00M 317.00M
Capital stock 387.00M 387.00M 328.00M 328.00M 317.00M
Retained earnings -574.00000M 1710.00M 5299.00M 2812.00M 5683.00M
Other liab 8499.00M 13011.00M 10491.00M 10283.00M 11114.00M
Good will 19820.00M 19997.00M 11845.00M 11668.00M 11707.00M
Other assets 4172.00M 5327.00M 4284.00M 3466.00M 2995.00M
Cash 6166.00M 6329.00M 7832.00M 5369.00M 4745.00M
Cash and equivalents - - - - -
Total current liabilities 26293.00M 22594.00M 20307.00M 18117.00M 16292.00M
Current deferred revenue - - - - -
Net debt 23066.00M 24452.00M 12548.00M 12858.00M 14368.00M
Short term debt 5542.00M 1893.00M 2386.00M 2010.00M 1754.00M
Short long term debt 5314.00M 1660.00M 2194.00M 1822.00M 1754.00M
Short long term debt total 29232.00M 30781.00M 20380.00M 18227.00M 19113.00M
Other stockholder equity 37224.00M 37171.00M 9995.00M 9987.00M 6468.00M
Property plant equipment 9449.00M 10171.00M 8917.00M 8335.00M 7421.00M
Total current assets 22593.00M 26244.00M 19544.00M 15563.00M 15591.00M
Long term investments - - - 1512.00M 978.00M
Net tangible assets -22090.00000M -23116.00000M -17170.00000M -19374.00000M -21198.00000M
Short term investments 239.00M 69.00M 160.00M 849.00M 809.00M
Net receivables 10521.00M 10758.00M 5651.00M 5181.00M 4837.00M
Long term debt 22965.00M 28134.00M 17505.00M 15730.00M 17359.00M
Inventory 4699.00M 8983.00M 4024.00M 3193.00M 2890.00M
Accounts payable 19040.00M 18938.00M 15785.00M 13987.00M 1720.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -8193.00000M -7517.00000M -7218.00000M
Additional paid in capital - - - - -
Common stock total equity - - 328.00M 328.00M 317.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1148.00M 1066.00M 1051.00M 1650.00M 1481.00M
Deferred long term asset charges - - - - -
Non current assets total 73890.00M 79119.00M 47185.00M 45814.00M 45060.00M
Capital lease obligations 953.00M 987.00M 681.00M 675.00M 0.00000M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2960.00000M 605.00M 1999.00M 125.00M 140.00M
Change to liabilities 1165.00M 1405.00M 1721.00M 868.00M -103.00000M
Total cashflows from investing activities -2960.00000M -11058.00000M -285.00000M -657.00000M 963.00M
Net borrowings -1441.00000M 7654.00M 1440.00M -1702.00000M 1473.00M
Total cash from financing activities -6823.00000M 3649.00M -2203.00000M -1765.00000M -2044.00000M
Change to operating activities - 2021.00M 361.00M 361.00M 361.00M
Net income 2501.00M -265.00000M 3916.00M 1548.00M 2155.00M
Change in cash -55.00000M -1508.00000M 2323.00M 552.00M 1499.00M
Begin period cash flow 6038.00M 7546.00M 5223.00M 4671.00M 3172.00M
End period cash flow 5983.00M 6038.00M 7546.00M 5223.00M 4671.00M
Total cash from operating activities 9808.00M 5963.00M 4799.00M 2969.00M 2618.00M
Issuance of capital stock 29.00M 29.00M 30.00M 3525.00M 34.00M
Depreciation 5480.00M 6530.00M 3149.00M 3762.00M 3753.00M
Other cashflows from investing activities 60.00M 54.00M 87.00M 274.00M 193.00M
Dividends paid 4364.00M 3856.00M 3572.00M 3592.00M 3484.00M
Change to inventory 3941.00M 1577.00M -621.00000M -316.00000M -13.00000M
Change to account receivables -1349.00000M -961.00000M -739.00000M -898.00000M -523.00000M
Sale purchase of stock -920.00000M 12413.00M 3049.00M 314.00M 34.00M
Other cashflows from financing activities -297.00000M -178.00000M -101.00000M 4.00M 2904.00M
Change to netincome -2491.00000M -615.00000M -1650.00000M -816.00000M -1709.00000M
Capital expenditures 2571.00M 2200.00M 2606.00M 2460.00M 1371.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3757.00M 2021.00M 361.00M -346.00000M -639.00000M
Stock based compensation - - - - -
Other non cash items -1930.00000M -2323.00000M -2627.00000M -1995.00000M -2651.00000M
Free cash flow 7237.00M 3763.00M 2193.00M 509.00M 1247.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AZN
AstraZeneca PLC		 -130.0 1.27% 10124.00 34.90 15.70 3.61 5.45 3.98 13.14
GSK
GlaxoSmithKline PLC		 -9.0 0.67% 1336.50 9.79 9.19 2.01 4.53 2.48 7.65

Reports Covered

Stock Research & News

View All

Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA

Key Executives

Name Title Year Born
Mr. Pascal Soriot D.V.M., M.B.A. CEO & Exec. Director 1959
Dr. Aradhana Sarin M.D. CFO & Exec. Director 1975
Mr. Marc Dunoyer CEO of Alexion & Chief Strategy Officer 1952
Ms. Pam P. Cheng EVP of Operations & Information Technology and Member of External Sustainability Advisory Board 1971
Mr. Chris Sheldon Head of Investor Relations NA
Mr. Jeffrey Pott Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board NA
Ms. Katarina Ageborg EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board NA
Gonzalo Vina Head of Global Media Relations NA
Dr. Menelas Pangalos Ph.D. EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board 1967
Dr. Ruud Dobber Ph.D. Exec. Vice-Pres of BioPharmaceuticals Bus. Unit NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions